Ocular findings associated with FADD deficiency resemble familial exudative vitreoretinopathy

Elana Meer a, Federica Solanes b, Lisa Kohn c, Caroline Y. Kuo c, Derek A. Wong d, Stacy Pineles b, Irena Tsui b,*,

a University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA
b Stein Eye Institute, Department of Ophthalmology, UCLA, USA
c Pediatric Allergy and Immunology, Department of Pediatrics, UCLA, USA
d Genetics, Department of Pediatrics, UCLA, USA

ARTICLE INFO

Keywords:
Fas-associated protein with death domain deficiency
Familial exudative vitreoretinopathy
Cystoid macular edema
Retinal ischemia
Retinal neovascularization
Tractional retinal detachment

ABSTRACT

Purpose: We report the first known case of eye findings associated with a Fas-associated protein with death domain (FADD) gene mutation, an exceedingly rare entity.

Observations: A 7-year-old boy was referred for decreased vision and eye examination revealed cystoid macular edema and peripheral retinal ischemia in both eyes and progression to tractional retinal detachment in the right eye.

Conclusions and Importance: This case suggests that baseline and annual ophthalmic screening may be beneficial in individuals with FADD mutations. However, greater documentation of cases may be necessary before deriving a clear interval screening recommendation.

1. Introduction

Fas-associated protein with death domain (FADD) deficiency is a rare and severe genetic mutation characterized by recurrent infections, encephalopathy, cardiac abnormalities, and short life expectancy. FADD, a novel death domain-containing protein located on the long arm of chromosome 11 (11q13.3), plays an important role in programmed cell death, a physiologic process essential to the normal development and homeostatic maintenance of multicellular organisms, as well as to cell proliferation, embryogenesis, and immune regulation.

There are only three families in reported in the literature, including the one we are describing. The purpose of this report is to describe novel eye findings associated with a FADD gene mutation.

2. Case report

A 7-year-old boy with compound heterozygous FADD gene mutations was referred to ophthalmology for acute visual loss in his right eye. Whole exome sequencing was previously performed and demonstrated two heterozygous FADD gene mutations in trans, c.52_58delAGCGAGC and c.313T>C, inherited from his mother and father respectively.

The patient was born full term to non-consanguineous parents with an uncomplicated prenatal and postnatal course. At 14 months old he presented with diarrhea, fever and vomiting with secondary dehydration. During this hospital admission, he had a tonic-clonic seizure episode and given a family history of an older brother who died at the age of 18 months with status epilepticus, possible sepsis and multi-organ failure with no known diagnosis, the patient underwent systemic and genetic evaluation. As part of genetic evaluation, he had an ophthalmologic exam by a pediatric ophthalmologist at 15 months (portable slit lamp exam, dilated fundus exam, pressure, motility), which demonstrated no abnormalities. A summary of the patient’s medical history is presented in Table 1. The patient had elevated Fas-ligand levels, with a decreased percentage of apoptosis seen on fas-mediated apoptosis testing (2%), high number of double negative T cells and elevated IL-10 level, biological features of autoimmune lymphoproliferative disorder (ALPS). Despite the presence of a spleen, Howell-Jolly Bodies were present in the blood smear, evidence of impaired splenic phagocyte function. He also demonstrated low antibody response to iso-hemagglutinins thought to be due a functional defect from the FADD mutation. In addition, physical exam was notable for hepatomegaly with a cholestatic picture of elevated LFTs at 15 months, which improved to a

* Corresponding author. 100 Stein Plaza, Los Angeles, CA, 90095, USA
E-mail address: itsui@jsei.ucla.edu (I. Tsui).

https://doi.org/10.1016/j.ajoc.2022.101305
Received 6 October 2020; Received in revised form 19 April 2021; Accepted 17 January 2022
Available online 3 February 2022
2451-9936/© 2022 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license

(http://creativecommons.org/licenses/by-nc-nd/4.0/).
mild persistent hepatomegaly (Table 1) The patient’s glucose and electrolytes were largely normal. White count was normal, though platelets were a bit low (~110) and with anemia (Hgb 9.8). A lumbar puncture was performed with 3WBC, 1RBC < glucose 59, but with protein 318. Genetic testing included exome sequencing to cover seizure genes, coagulation genes (For stroke risk), polymerase gamma, as well as mitochondrial liver disease, with FADD mutations as specified above.

The patient presented to ophthalmology at 7 years old with acute vision loss. Ophthalmologic exam revealed visual acuity of 20/400 in the right eye and 20/60 in the left eye (Table 2). Anterior segment exam was unremarkable and dilated fundus exam showed neovascularization of the optic disc with a tractional retinal detachment and associated vitreous hemorrhage in the right eye (Fig. 1), bilateral peripheral retina ischemia (Fig. 1), and bilateral cystoid macular edema (CME) (Fig. 2). The left eye did not have retinal vitreous hemorrhage or retinal detachment.

The patient underwent an exam under anesthesia with targeted retinal photocoagulation in both eyes and an injection of anti-vascular endothelial growth factor (ranibizumab 0.25 mg/.05 cc) in the left eye, supplemented by neopafenix twice daily, with stabilization of symptoms. Patient was lost to follow-up for 5 months due to COVID-19. When he represented, vision was stable (20/400 in the right eye and 20/70 in the left eye), and CME in his left eye had improved (Fig. 3). The patient was recommended to undergo pars plana vitrectomy in the right eye for vitreous hemorrhage and tractional retinal detachment. The patient was lost to follow-up due to an extended outside hospitalization for neurological issues. At the most recent follow-up, 1 year after his EUA/laser/injection, vision was HM in the right eye, 20/60 in the left eye for vitreous hemorrhage and tractional retinal detachment. The patient was recommended to undergo pars plana vitrectomy in the right eye for vitreous hemorrhage and tractional retinal detachment.

Table 1
Comparative Clinical Presentations of Patients with FADD deficiency.

| Mutation          | Bolze (2010) | Savic et al.(2015) | This Case | Patient’s Brother |
|-------------------|-------------|--------------------|---------|-------------------|
| G; p.C105W homozygous | c.315T > G | c.315T > G; p.C105W homozygous | c.52,58delAGCGAGC, c.313T > C compound heterozygous |
| Gender            | 1 male, 3 female | 2 female, 2 male | Male | Male |
| Cardiovascular malformation | Pulmonary atresia + VSD, L sided SVC draining to left atrium | Presence of congenital cardiac abnormalities | Echocardiogram was previously performed and found to be normal | Echocardiogram was previously performed and found to be normal |
| Functional hypoplenism | Spleen size normal | Suboptimal anti-pneumococcal antibody titers despite repeated Prevnar 13 vaccination | Invasive pneumococcal infections | Invasive pneumococcal infections |
| Features of febrile episodes | Documented viral trigger (V2V, HHV6, MMR vaccine, astrovirus, parainfluenza 2, EBV) | Documented Recurrent viral Infections, encephalopathy, seizures, pneumococcal meningitis | Documented recurrent infections, encephalopathy, seizures | Triggred by MMR vaccine |
| Spleen size | normal | normal | normal | Encephalopathy |
| Liver dysfunction | Liver dysfunction (maximal ALT 1042) | | | Seizures |
| APLS phenotype | Autoimmune disease | Normal Immunoglobulin profile and complement studies | No autoimmunity - demonstrates low antibody response to isohemagglutinins | Elevated CD4-CD8- TCR T cells |
| CNS | Neurodevelopmental progress | Negative autoimmune screen | Elevated Serum FasL, IL10 | Elevated Serum FasL, IL10 |
| Ophthalmology | Mild chronic portal inflammation with bridging fibrosis, elevated ALT | Marginal elevation in CD4-CD8- T cells | Speech delay | Speech delay |
| Liver | Mild chronic portal inflammation with bridging fibrosis, elevated ALT | Marginal elevation in CD4-CD8- T cells | | |
| Neurodevelopmental progress | Neurodevelopmental progress | Marginal elevation in CD4-CD8- T cells | Speech delay | Speech delay |
| Follow up data | (1) Died at 4 months (2) Died at 14 months (3) Died at 4 years 4 months (4) Alive at 2 years 9 months in 2010 without further follow up data | | (1) Alive at 8 years | (1) Died at 18 months |

Table 2
Ophthalmologic findings in patient.

| OD       | OS       |
|----------|----------|
| Visual Acuity | 20/400 + 1 | 20/60-2 |
| Tonometry   | normal   | normal |
| Pupillary Reflex | normal | normal |
| Visual Fields  | normal | normal |
| Slit Lamp exam  | normal | normal |
| Motility     | normal | normal |
| Alignment    | normal | normal |
| Cycloplegic Refraction | +0.50 + 1.00x90’ | plano +1.50x90’ |
| Fundus Exam (Fig. 1) | Neovascularization of the optic nerve with tractional retinal detachment and associated vitreous hemorrhage + cystoid macular edema |
| Wide Field Fluorescein Angiography (Fig. 2) | Periretinal Retinal Ischemia and Neovascularization |
| Macular OCT (Fig. 3) | Cystoid Macular Edema with central subretinal Fluid |
| B-Scan (Fig. 4) | Clusters of dense opacities anteriorly with a vitreous membrane and peri-papillary vitreoretinal adhesions | Deferred (retina attached) |
eye. The vitreous hemorrhage in the right eye had worsened with no view to the back. B-scan of the right eye showed stable tractional retinal detachment. The left eye was stable with improved CME and good laser treatment with peripheral laser. Pars plana vitrectomy was recommended in his right eye and is pending pre-operative clearance. The left eye had notable neovascularization of the disc without neovascularization seen in the retina periphery and resolved CME on OCT. The patient will have additional laser and anti-VEGF injection in the left eye at the time of right eye surgery.

3. Discussion

In this report, we present a 7-year-old boy with FADD deficiency (MIM 613759), the oldest reported patient with this disease. The patient had systemic manifestations similar to previously reported families, namely recurrent febrile episodes, encephalopathy, seizures, lymphadenopathy/splenomegaly (Table 1). There are no prior eye findings reported with FADD deficiency, likely because it is exceedingly rare with a short life expectancy and visual dysfunction is confounded by severe neurological dysfunction.

This patient presented with CME and peripheral retina ischemia in both eyes and a tractional retinal detachment in one eye. This presentation is similar to familial exudative vitreoretinopathy (FEVR), an inherited disorder of retinal angiogenesis with variable expressivity. Although variable, clinical presentation of FEVR is classically isolated to the eye, and involves peripheral retinal ischemia, pre-retinal vascularization and fibrosis with CME as seen in this case. Genetic analysis in this patient demonstrated FADD deficiency without mutations identified in known FEVR genes. While the importance of this case from an immunologic standpoint has been reported in the literature, this report uniquely discusses the ophthalmologic manifestations and management.

FADD, a novel death domain-containing protein located on the long arm of chromosome 11 (11q13.3), plays an important role in programmed cell death, a physiologic process essential to the normal development and homeostatic maintenance of multicellular organisms, as well as to cell proliferation, embryogenesis, and immune regulation. Signal transduction mediated by FADD represents a paradigm of co-regulation of apoptosis and cellular proliferation. FADD is involved in the early signal transduction process that allows for the TNF alpha-FAS-FADD complex to lead to caspase activation and ensuing apoptosis. Mutations in FADD abolish its ability to bind the domains of Fas and TNFR-1 and subsequently activate caspase 8 responsible for triggering cell death. Therefore, as a crucial regulator of life and death of certain cells, FADD deficiency has many systemic findings, manifesting with recurrent febrile episodes, encephalopathy, seizures, variable degrees of lymphadenopathy or splenomegaly, cerebral atrophy,
The phenotypic similarities between FEVR, an inherited disorder of retinal angiogenesis, and the ocular findings in this patient with FADD deficiency may be explained by their shared pathway, as well as adjacent gene locus on chromosome 11.13, leading to altered caspase 8 activity and downregulation of apoptosis.\textsuperscript{2,4} TNF-alpha, the initiator of the caspase activating cascade, has been shown to contribute to ischemic retinopathy as elevated expression is associated with increased upstream activation of FAS-FADD-caspase activation and ischemic neuronal injury.\textsuperscript{3} We hypothesize that dysfunction of this cascade may lead to continuous inflammation in the retina secondary to endothelial dysfunction, and ensuing retinal ischemia with reactive neovascularization similar to FEVR.\textsuperscript{2,5} It is also possible that the peripheral retina ischemia was more a manifestation of vaso-obliteration or an associated developmental abnormality in which the vessels did not make it out all the way to the periphery of the retina in utero. Furthermore, compensatory overexpression of TNF alpha, the initiator of the cascade may modulate ion channel activity causing excitotoxic injury to retinal...
ganglion cells in the retina, and independently induce angiogenesis through increasing vascular permeability and VEGF secretion. It is also important to note that FEVR is phenotypically and genotypically variable, and not all contributory genes and mutations are known. Therefore, while the pathophysiology of a FADD mutation is in line with the clinical presentation as described, it is still difficult to completely rule out FEVR as a separate diagnosis in this case.

4. Conclusions

In summary, this case heralds the ophthalmic manifestations of FADD deficiency. Currently there have been only two other known families with FADD mutations reported in the literature, both consanguineous. The significance of our patient’s genetic mutations and systemic manifestations has been previously reported, however, we give further importance to the common role of the TNF alpha-FAS-FADD-caspase8/3 programmed cell death pathway in sustaining systemic immune and retinal cells. Baseline and annual ophthalmic screening may be beneficial in individuals with FADD mutations. However, greater documentation of cases may be necessary before deriving a clear interval screening recommendation.

Patient consent

Consent to publish the case report was not obtained. This report does not contain any personal information that could lead to the identification of the patient.

Funding

Unrestricted grant from Research to Prevent Blindness given to Stein Eye Institute.

Authorship

All authors attest that they meet the current ICMJE criteria for Authorship.

Appendices

None.

Declaration of competing interest

None of the authors have financial disclosures

Acknowledgements

None.
References

1. Bolze A, Byun M, McDonald D, et al. Whole-exome-sequencing-based discovery of human FADD deficiency. Am J Hum Genet. 2010;87(6):873–881.

2. Rao P, Lertjirachal I, Yonekawa Y, et al. Etiology and clinical characteristics of macular edema in patients with familial exudative vitreoretinopathy. Retina. 2019;40(7):1367–1373.

3. Chinnaiyan AM, O’Rourke K, Tewari M, et al. FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell. 1995;81(4):505–512.

4. Shin HW, Park SY, Lee KB, et al. Down-regulation of Wnt signaling during apoptosis of human hepatic stellate cells. Hepato-Gastroenterology. 2009;56(89):208–212.

5. Al-Gayyar MM, Elsherbiny NM. Contribution of TNF-α to the development of retinal neurodegenerative disorders. Eur Cytokine Netw. 2013;24(1):27–36.

6. Savic S, Parry D, Carter C, et al. A new case of Fas-associated death domain protein deficiency and update on treatment outcomes. J Allergy Clin Immunol. 2015;136(2):502–505.

7. Kohn LA, Long JD, Trope EC, et al. Novel Compound Heterozygote Variations in FADD identified to cause FAS-associated protein with death domain deficiency. J Clin Immunol. 2020;40(4):658–661. Epub ahead of print.

8. Wajant H. The Fas signaling pathway: more than a paradigm. Science. 2002;296:1635–1636.

9. Mouasni S, Tourneur L. FADD at the crossroads between cancer and inflammation. Trends Immunol. 2018;39(12):1036–1053.